Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.71 |
| ▸ | TTR | P02766 | 3/20 | 0.71 |
| ▸ | CA12 | O43570 | 2/20 | 0.71 |
| ▸ | CA1 | P00915 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486726 | 1.00 | PTGS1 (1.00) | PTGS1KDM4ELMNAPTGS2MEN1 | |
| SCHEMBL3679880 | 0.91 | PTGS1 (0.84) | PTGS1KDM4ELMNAPTGS2MEN1 | |
| SCHEMBL3679884 | 0.91 | PTGS1 (0.84) | PTGS1KDM4ELMNAPTGS2MEN1 | |
| SCHEMBL18131915 | 0.86 | PTGS1 (0.73) | PTGS1KDM4ELMNAPTGS2MEN1 | |
| Resveratrol SCHEMBL20164915 | 0.83 | PTGS1 (1.00) | PTGS1KDM4ELMNAPTGS2MEN1 | |
| Resveratrol SCHEMBL19426 | 0.83 | PTGS1 (1.00) | PTGS1KDM4ELMNAPTGS2MEN1 | |
| Resveratrol SCHEMBL3704258 | 0.83 | PTGS1 (1.00) | PTGS1KDM4ELMNAPTGS2MEN1 | |
| Resveratrol SCHEMBL17629801 | 0.83 | PTGS1 (1.00) | PTGS1KDM4ELMNAPTGS2MEN1 | |
| Cis-Resveratrol SCHEMBL1931746 | 0.83 | PTGS1 (1.00) | PTGS1KDM4ELMNAPTGS2MEN1 | |
| Resveratrol SCHEMBL2300985 | 0.83 | PTGS1 (1.00) | PTGS1KDM4ELMNAPTGS2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2021-07-29 | — | — | US | disclosed |
| US-10426742-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2019-01-24 | — | — | US | disclosed |
| EP-1753708-B1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2016-10-13 | — | — | US | disclosed |
| EP-2362226-B1 | Diagnostic method for neurodegenerative diseases based on measurement of SIRT1 levels or activity | HARVARD COLLEGE (US) | 2016-02-17 | — | — | EP | disclosed |
| US-8841477-B2 | Sirtuin activating compounds and processes for making the same | BRIGHAM YOUNG UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2289504-A2 | SIRT1 modulators for manipulating cell/organism lifespan/stress response | President and Fellows of Harvard College (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-2236131-A2 | Compositions for manipulating the lifespan and stress response of cells and organisms | President and Fellows of Harvard College (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY (US) | 2010-07-22 | — | — | US | disclosed |
| US-7714161-B2 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| EP-1670484-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| US-20060084135-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | BIOMOL INTERNATIONAL, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| WO-2005032559-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | NOS2, NOS3, NOS1 | PTGS1 98/4885KDM4E 1993/4885LMNA 2355/4885 |
| US-11786481-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | PTGS1 1684/4885KDM4E 1611/4885LMNA 2060/4885 |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | PTGS1 1421/4885KDM4E 1739/4885LMNA 2142/4885 |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | ATG7, SQSTM1, ATF4 | PTGS1 1642/4885KDM4E 1284/4885LMNA 2342/4885 |
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | SIRT1, SIRT2, SIRT3 | PTGS1 4110/4885KDM4E 438/4885LMNA 1305/4885 |
| US-10426742-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | PTGS1 1684/4885KDM4E 1611/4885LMNA 2060/4885 |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | PTGS1 1684/4885KDM4E 1611/4885LMNA 2060/4885 |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | NOS2, NOS1, NOS3 | PTGS1 101/4885KDM4E 2159/4885LMNA 1781/4885 |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | RB1, SBK1, NADK | PTGS1 3702/4885KDM4E 1793/4885LMNA 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.